Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Protein chip for chronic hepatitis C outcome prediction in chronic hepatitis C interferon treatment

A protein chip and interferon technology, applied in the field of protein chips, can solve the problems of high treatment cost and long medication cycle, and achieve the effects of convenient clinical application, convenient detection, and reduced pain for patients

Inactive Publication Date: 2012-06-06
PEOPLES HOSPITAL PEKING UNIV
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Interferon-alpha (IFN-α) combined with ribavirin is currently the most effective treatment, but it requires subcutaneous injection of medication, the medication cycle is very long, the cost of treatment is expensive, and there are many adverse factors such as side effects of drugs; and interference HCV sustained virological response after antibiotic therapy is only about 50%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protein chip for chronic hepatitis C outcome prediction in chronic hepatitis C interferon treatment
  • Protein chip for chronic hepatitis C outcome prediction in chronic hepatitis C interferon treatment
  • Protein chip for chronic hepatitis C outcome prediction in chronic hepatitis C interferon treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0040] 10ml of anticoagulated blood was taken from 12 patients with chronic hepatitis C before treatment with long-acting interferon plus ribavirin, and peripheral blood mononuclear cells were separated by Ficoll density gradient centrifugation. The separated mononuclear cells were equally divided into control group and experimental group. Group. The control group was cultured with DMEM medium for 48 hours, and the experimental group was treated with DMEM medium containing 100 U / ml IFNα for 48 hours to extract the protein of the above samples.

[0041] The protein chip was used to detect the change value of the relative expression level of ISG in the experimental group and the control group, and the total score of ISG was evaluated according to the above scoring standard, as shown in Table 2, in which:

[0042] The total ISG expression score of protein chip in 5 patients was 33-39 points (group 1), predicting that the probability of obtaining sustained virological response aft...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a protein chip for chronic hepatitis C outcome prediction in chronic hepatitis C interferon treatment. The protein chip comprises protein fragments corresponding to 13 genes of ISG56, ISG20 and the like. Through the protein chip, in an early stage of chronic hepatitis C interferon treatment on patients or before the chronic hepatitis C interferon treatment on patients, interferon treatment long-term effects can be predicted. Therefore, the protein chip is conducive to optimization and selection of a chronic hepatitis C patient therapeutic schedule, reduces patient pain and treatment costs, and is convenient for detection and clinical application.

Description

【Technical field】 [0001] The invention relates to a protein chip, in particular to a chronic hepatitis C outcome prediction protein chip. 【Background technique】 [0002] Hepatitis C virus (HCV) infection is one of the most important viral infectious diseases at present. About 170 million people in the world are chronically infected with HCV, and chronic HCV infection may further develop into liver cirrhosis or even liver cancer. As there is currently no effective vaccine, there are still three to four million new HCV infections each year. Interferon-alpha (IFN-α) combined with ribavirin is currently the most effective treatment, but it requires subcutaneous injection of medication, the medication cycle is very long, the cost of treatment is expensive, and there are many adverse factors such as side effects of drugs; and interference The sustained virologic response to HCV after antibiotic therapy is only about 50%. Therefore, the discovery of factors that can predict the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
Inventor 潘孝本魏来
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com